组织型激肽释放酶及相关肽酶在中枢神经系统中的作用

组织型激肽释放酶1(kallikrein1,KLK1)和激肽释放酶相关肽酶(kallikrein-related peptidase 2～15,KLK2～15)是一类丝氨酸蛋白酶,具有广泛的生物学活性。在中枢神经系统中,它们不但在脑的生长、发育和学习记忆等方面起重要作用,同时也在多种脑部疾病中起重要作用,如帕金森病、痴呆、多发性硬化、肿瘤等,并在这些疾病的诊断、治疗和预后方面显示出潜在的应用价值。     

人体激肽释放酶2与前列腺癌

人体激肽释放酶2(human kallikrein 2,hK2)是一种主要在前列腺中表达的丝氨酸蛋白酶,近年作为前列腺癌的血清标记物受到广泛关注.随着对hK2结构特征、组织表达、生物学活性和调节,及其与前列腺癌病理过程的关系的研究更一步深入,hK2在前列腺癌诊断、病理分期及治疗中的潜在应用价值将越加瞩目.     

血浆激肽释放酶新底物PK—120的研究

血浆激肽释放酶新底物ＰＫ┐１２０的研究蒲小平（军事医学科学院基础医学研究所,北京１００８５０）关键词血浆激肽释放酶底物１．发现补体系统由２０余种血浆蛋白组成,在机体防御和炎症应答反应中起重要作用。１９８９年Ｈａｍｍｅｒ等在用Ｃ４ｂ－Ｓｅｐｈａｒｏｓｅ...     

化学修饰对胰激肽释放酶稳定性及其性质的影响

以自制高活性ＰＰＫ为材料，在氰基硼氢化钠存在下经水溶性乙醛酸修饰其表面氨基，使基抗不可逆热失活稳定性有显著提高，结果表明，修饰ＰＰＫ在等电点等基本性质方面都有变化，修饰ＰＰＫ的ＢＡＥＥ活性为天然酶的８２％，氨基修饰度为５８％，抗蛋白酶水解，贮藏和冻干稳定性都有加强。     

人组织激肽释放酶基因在哺乳动物细胞中的表达

克隆人胰腺组织激肽释放酶基因 (hKK) ,构建融合荧光蛋白基因的真核表达载体 ,在CHO细胞中表达 ,为开发激肽释放酶基因工程产品以及开展基因治疗高血压研究奠定了基础。提取人胰腺组织总RNA后 ,RT PCR扩增KK ,构建中间载体KSKK。从KSKK中切出激肽释放酶基因 ,插入真核表达载体pEGFP C2 ,构建出激肽释放酶带有荧光蛋白报告基因的表达载体pEGC KK ,测序分析后转染CHO细胞 ,荧光显微镜观察激肽释放酶基因表达。并进行SDS PAGE及Westernblot分析。成功克隆激肽释放酶基因 ,并在CHO细胞获得表达 ,克隆的人组织激肽释放酶基因可用于激肽释放酶基因工程产品开发以及基因治疗研究。     

蛇毒类激肽释放酶的研究进展

蛇毒丝氨酸蛋白酶是蛇毒中一类丰富的蛋白水解酶,具有重要的临床应用价值。其中一种丝氨酸蛋白酶一类激肽释放酶,作用于激肽原释放激肽,引起血管舒张,改善微循环,从而逐渐受到关注。对蛇毒中类激肽释放酶的分布、分离制备、生化性质、结构研究和药效研究等方面进行了综述,同时指出了目前存在的问题及今后的发展方向,以期为进一步的基础研究提供理论基础。     

用昆虫细胞表达系统表达人组织激肽释放酶原

目的:利用杆状病毒-昆虫细胞表达系统表达proHUK,系统优化表达条件。方法:用改进的方法对昆虫细胞进行了无血清悬浮适应培养,用ELISA、SDS-PAGE方法对各种条件下proHUK的表达量进行检测。结果:Sf-9、Hi-5细胞在血清减量速度为5%、1%,接种密度分别为2×106cells/mL1、×106cells/mL时能很快适应无血清悬浮培养。在病毒感染复度MOI为10,细胞接种密度为1×106cells/mL条件下培养96h后,proHUK的表达量最高可达30mg/L。结论:改进的方法使昆虫细胞能更快适应无血清悬浮生长条件,获得了高表达proHUK的方法,为其大规模制备奠定了基础。     

人组织激肽释放酶成熟蛋白在大肠杆菌中的高效表达

将编码人组织激肽释放酶成熟蛋白的基因片段扩增并分别克隆到原核表达载体pET2 8(b)及分泌型表达载体pET2 0 (b)中 ,使其C端融合 6×HisTag序列 .转化不同受体菌 ,IPTG诱导表达后利用SDS PAGE、免疫印记等方法对重组蛋白进行分析 .在 6株基因工程菌株中 ,均表达出分子量约30kD的激肽释放酶融合蛋白 ,其中激肽释放酶在pET2 8载体中的表达水平高于pET2 0载体 .pET2 8和pET2 0载体表达的重组激肽释放酶蛋白分别占菌体总蛋白约 2 6 %和 10 % .Western印迹分析表明 ,目的蛋白可与抗人血清KK单克隆抗体发生特异性反应 .未经纯化的激肽释放酶融合蛋白具有一定的水解苯甲酰精胺酸乙酯 (BAEE)的能力 .在大肠杆菌中获得了人组织激肽释放酶的高效表达 ,表达产物具有免疫原性和生物活力 ,这为研究其生物功能和开发基因工程药物奠定基础     

人组织激肽释放酶4在激素依赖性肿瘤中的研究进展

人组织激肽释放酶基因家族由KLK1-KLK15构成,编码一组丝氨酸蛋白酶。研究发现KLK基因家族涉及癌细胞的多种生物学功能,且其表达受类固醇激素的调节。人组织激肽释放酶4是丝氨酸蛋白酶家族的一个成员,在多种激素依赖性肿瘤如卵巢癌、前列腺癌、乳腺癌、子宫内膜癌中高表达,且表达量受雌激素、孕激素、雄激素不同程度的调节。近年来很多文献报道人组织激肽释放酶4涉及癌细胞的增殖、上皮间质转化及细胞外基质的降解等过程,可能促进了肿瘤的发生、发展,且与激素依赖性肿瘤的预后不良有关。这些研究显示人组织激肽释放酶4与激素依赖性肿瘤关系密切,是其潜在的肿瘤标记物和治疗靶点,随着研究的进一步深入,有望应用于激素依赖性肿瘤的早期诊断、病程监测和治疗。     

组织激肽释放酶在肿瘤发展中的作用

组织激肽释放酶(kallikrein-related peptidases,KLKs)是人类基因组中已知最大的丝氨酸蛋白酶家族。KLKs主要存在于体液和组织中,参与了广泛的生理过程,它们的异常调节与肿瘤的发生发展密切相关。该文总结了KLKs参与肿瘤发生发展的相关机制,以及部分KLKs成员在肿瘤发展进程中发挥的重要作用,综述了它们所介导的肿瘤发展进程以及作为肿瘤生物标志物和候选治疗靶点的研究进展。     

The kallikrein-kinin system in the rat hypothalamus

Summary High molecular weight kininogen (HKg) and T kininogen (TKg) were detected and localized by immunocytochemistry in adult rat hypothalamus. In addition, kininogens were measured by their direct radioimmunoassay (RIA) or by indirect estimation of kinins released after trypsin hydrolysis and high pressure liquid chromatography (HPLC) separation of bradykinin (BK) and T kinin. A specific HKg immunoreactivity demonstrated with antibodies directed against the light chain (LC) of HKg was colocated with SRIF in neurons of hypothalamic periventricular area (PVA) projecting to external zone (ZE) of median eminence (ME). Heavy chain (HC) immunoreactivity which could be related to HKg or to low molecular weight kininogen (LKg) was detected in some other systems: i) parvocellular neurons of suprachiasmatic (SCN) and arcuate nuclei containing SRIF, ii) magnocellular neurons (mostly oxytocinergic) of paraventricular (PVN) and supraoptic (SON) nuclei, iii) neurons of dorsomedian and lateral hypothalamic areas. TKg immunostaining was restricted to magnocellular neurons of PVN, SON, accessory nuclei (mostly vasopressinergic) and to parvocellular neurons of SCN (vasopressinergic). TKg projections are directed towards the internal zone (ZI) of ME, but very few immunoreactive terminals are detectable in neurohypophysis. TKg staining parallels with vasopressin during water deprivation, and is undetectable in homozygous Brattleboro rats. In some magnocellular neurons, TKg and HC (related to HKg or LKg) are coexpressed. TKg, was also detected in hypothalamus and cerebellum extracts by direct RIA, and BK and T kinin were identified after trypsin hydrolysis. HKg and LKg can act as precursor of BK which can play a physiological role as releasing factor, neuromodulator — neurotransmitter, — or modulator of local microcirculation in hypothalamus. The three kininogens are also potent thiolprotease inhibitors which could modulate both the maturation processes of peptidic hormones and their inactivation and catabolism.     

Role of the kallikrein-kinin system in glandular secretion

Microsomes were prepared from liver, lung and kidney of rats and rabbits using a Ca⁺² aggregation method. Microsomal protein yield from the lung of both species was higher by this method of preparation as compared with ultracentrifuged samples. Specific activities of rat and rabbit pulmonary p-chloro-N-methylaniline (CMA) demethylase, biphenyl 4-hydroxylase and rat pulmonary TPNH cytochrome c reductase also were decreased. Specific activities of rabbit hepatic TPNH cytochrome c reductase, CMA N-demethylase, UDP-glucuronyltransferase and biphenyl hydroxylase were decreased by calcium aggregation Renal enzyme activities were unchanged by this method of preparation. These data indicate an apparent species and organ difference in microsomal enzyme response to calcium aggregation.     

Key enzymes of the kallikrein-kinin system in Antarctic teleosts

In this study, some of the mammalian kallikrein-kinin system (KKS)-like components were identified in two species of Antarctic notothenioid [Chionodraco hamatus (Channichthydae) and Trematomus bernacchii (Nothothenidae)]. The kidney and heart were assayed for kallikrein-like activity using the synthetic substrate d-Val-Leu-Arg-paranitroanilide. Values expressed as nmol p-nitroanilide/mg proteins, were in C. hamatus 15.5±1.5 and 15.2±1.4 in kidney and heart, respectively, and 15.8±2.2 and 15.9±1 in kidney and heart of T. bernacchii. Kallikrein-like activity was inhibited bvy aprotinin and phenylmethylsulfonyl fluoride (PMSF). The assay was stable at 20°C. Kininase II-like activity was performed on kidney, gills and heart using the substrate hippuryl-lhistidyl-l-leucine. The activity was inhibited by captopril, and in kidney and gills by high temperatures (20°C and 37°C); in the heart the enzymatic activity was measurable also at 20°C. Bradykinin-like immunoreactive cells were localized by immunohistochemistry in the nephron, in the gills, and in the arterial walls of the heart. These results show that Antarctic teleosts possess elements comparable to those of the KKS, including kallikrein-like, and kininase II-like activities, and the end product of the enzymatic cascade, bradykinin. The enzymatic cascade appears to be fully active only at low temperatures. Received: 19 April 1996/Accepted: 30 June 1996     

Genetically altered animal models in the kallikrein-kinin system

Transgenic and gene-targeting technologies allowing the generation of genetically altered animal models have greatly advanced our understanding of the function of specific genes. This is also true for the kallikrein-kinin system (KKS), in which some, but not yet all, components have been functionally characterized using such techniques. The first genetically altered animal model for a KKS component was supplied by nature, the brown Norway rat carrying an inactivating mutation in the kininogen gene. Mice deficient in tissue kallikrein, B1 and B2 receptors, some kinin-degrading enzymes, and factor XII followed, together with transgenic rat and mouse strains overexpressing tissue kallikrein, B1 and B2 receptors, and degrading enzymes. There are still no animal models with genetic alterations in plasma kallikrein, kininases I and some other degrading enzymes. The models have confirmed an important role of the KKS in cardiovascular pathology, inflammation, and pain, and have partially elucidated the distinct function of the two receptors. This created the basis for rational decisions concerning the putative use of kinin receptor agonists and antagonists in therapeutic applications. However, a more thorough analysis of the existing models and the generation of new, more sophisticated transgenic models will be necessary to clarify the still elusive issue as to where and by which mechanisms the kinins exert their actions.     

Spatial expression of the kallikrein-kinin system during nephrogenesis

During nephrogenesis, new nephrons are induced in the periphery of the kidney, while maturing nephrons occupy a deeper position in the renal cortex. This centrifugal pattern of maturation is characterized by nephron patterning, establishment of proximal-distal segment identity, tubular and glomerular growth and differentiation, and acquisition of specialized functions. All of these processes are coordinated in time and space with renal vasculogenesis, glomerulogenesis and regional hemodynamic changes. The end-result ensures that tubular structure and function are tightly coordinated with glomerular filtration during normal kidney development. To achieve this delicate task of glomerulotubular balance, the developing kidney produces growth factors and vasoactive hormones that act in a paracrine manner to regulate nephrovascular growth, differentiation and physiological functions. One such paracrine system is the kallikrein-kinin system (KKS), which generates bradykinin (BK) from the cleavage of kininogen by kallikrein. BK activates a G-protein coupled receptor, B2R, to regulate renal blood flow and salt and water excretion. The developing kidney expresses an endogenous KKS. Expression of the KKS components and B2R is intimately coordinated with the terminal differentiation of the distal nephron. Kallikrein marks the onset of connecting tubule development, whereas kininogen and B2R map to the developing ureteric bud branches and maturing collecting ducts.Gene targeting studies indicate that the fetal KKS plays an important role in the maintenance of terminal epithelial cell differentiation.     

Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans

We used cardiopulmonary bypass (CPB) as a model of activation of the contact system and investigated the involvement of the plasma and tissue kallikrein-kinin systems (KKS) in this process. Circulating levels of bradykinin and kallidin and their metabolites, plasma and tissue kallikrein, low and high molecular weight kininogen, and kallistatin were measured before, during, and 1, 4, and 10 h after CPB in subjects undergoing cardiac surgery. Bradykinin peptide levels increased 10- to 20-fold during the first 10 min, returned toward basal levels by 70 min of CPB, and remained 1.2- to 2.5-fold elevated after CPB. Kallidin peptide levels showed little change during CPB, but they were elevated 1.7- to 5.2-fold after CPB. There were reductions of 80 and 60% in plasma and tissue kallikrein levels, respectively, during the first minute of CPB. Kininogen and kallistatin levels were unchanged. Angiotensin-converting enzyme inhibition did not amplify the increase in bradykinin levels during CPB. Aprotinin administration prevented activation of the KKS. The changes in circulating kinin and kallikrein levels indicate activation of both the plasma and tissue KKS during activation of the contact system by CPB.